Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | RARG | P13631 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25747945 | 0.89 | L3MBTL1 (0.40) | TDP1L3MBTL1KMT2AHTTNR4A2 | |
| SCHEMBL25226030 | 0.85 | CCR1 (0.36) | TDP1L3MBTL1KMT2AHTTCYP11B2 | |
| SCHEMBL30424138 | 0.84 | MAPT (0.45) | L3MBTL1MAPTALDH1A1 | |
| SCHEMBL25208325 | 0.84 | MAPT (0.45) | L3MBTL1MAPTALDH1A1 | |
| SCHEMBL20604795 | 0.78 | CYP1A2 (0.45) | KMT2APTGDR2NR4A2MAPTALDH1A1 | |
| SCHEMBL25751171 | 0.73 | PDE5A (0.35) | RARGRORC | |
| SCHEMBL702834 | 0.71 | CCR1 (0.45) | L3MBTL1KMT2ACCR1MAPTALDH1A1 | |
| SCHEMBL27832046 | 0.70 | CCR1 (0.43) | L3MBTL1KMT2ACCR1MAPTALDH1A1 | |
| SCHEMBL1395071 | 0.69 | TDP1 (0.43) | TDP1L3MBTL1KMT2AALDH1A1LMNA | |
| SCHEMBL20604857 | 0.66 | NR4A2 (0.56) | KMT2ANR4A2MAPTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230202984-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202984-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | VHL, TP53, MCL1 | TDP1 343/4885L3MBTL1 2056/4885KMT2A 2982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.